-- The odds of functional independence defined as a modified Rankin Score (mRS) </= 1 were significantly increased at 6 months and persisted up to 18 months after stroke in the NeuroAiD™ group.
Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases. It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients' recovery after an ischemic stroke. The CHIMES-E study results were first announced by Prof. Christopher Chen (CHIMES-E co-principal investigator) during the European Stroke Organization Conference (ESOC 2015) in Glasgow, April 17-19, as part of the Scientific Program during the Clinical Trial session.
The CHIMES-E study is a planned, international and multicenter study performed in a blinded and placebo-controlled manner. It has included 880 patients from the CHIMES study who have suffered an ischemic stroke of intermediate severity within 72 hours, treated with NeuroAiD™ or placebo for 3 months after the initial stroke. The main purpose of this study was to evaluate the effects of an initial 3-month course with NeuroAiD™ on long-term outcomes for up to 2 years.
This study has showed that NeuroAiD™ increases significantly the odds of achieving functional independence at 6 months which persisted up to 18 months after stroke, as measured by the mRS. All these results were consistent at various time points and seen on 2 indices, i.e. mRS and BI. It also provided further long-term safety data on NeuroAiD™, even when combined with other stroke treatments. "These persistent benefits seen up to 18 months are a clinical confirmation of the previously established neurorestorative properties (i.e. neuroplasticity and neurogenesis) of NeuroAiD™, and suggest that it may be beneficial to extend NeuroAiD™ treatment beyond the first 3 months after stroke," said Prof. Christopher Chen, neurologist at the National University of Singapore and the principal investigator of the CHIMES study. "The CHIMES-E study provides new insight on the need for long-term assessment of post-stroke recovery in clinical trials of agents with neuroprotective and neurestorative properties such as NeuroAiD."
These results confirm the hypothesis raised by the CHIMES investigators: longer treatment duration and follow-up beyond 3 months of stroke patients is needed to assess stroke recovery.
Practical tool helps predict epilepsy risk in venous stroke patients